

Update week 19 & 20 - 2023

Dr. Peter Lansberg is a Dutch lipidologist, educator and innovator. He has been instrumental in setting up The Dutch National Lipid Clinic Network, the Dutch Lipid Clinic Criteria for Familial Hypercholesterolemia (FH), and the Dutch National FH screening program

---

The Statin Newsletter will keep you up-to-date with all recent statin publications. Based on a curated approach to select relevant articles.

For live updates you can follow me on twitter

Key Publications

1. **Can we use statins in patients with NAFLD/NASH?**
2. **Statins differ in risk for rhabdomyolysis**
3. **Coronary artery spasm can statins help?**
4. **High intensity statins improve neurologival outcomes in SSSI patients**
5. **Tool can help to predict SAMS**

register for 37th WCIM - Prague 30/10-2/11 2024!

Can statins improve NASH?

This article reviews the diagnosis and management patterns of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) in real-world settings. The study utilized a large database of over 2,000 NASH patients treated by 170 physicians across various specialties. The analysis revealed several key findings. Firstly, a relatively high proportion of patients (over 70%) underwent liver biopsy, which is greater than reported in other real-world settings. However, there was a trend among physicians to rely on non-invasive tests, such as imaging and blood tests, to diagnose advanced fibrosis (cirrhosis) rather than performing biopsies. The study also found that the utilization of non-imaging-based methods to assess liver fibrosis was highly variable, highlighting the potential benefit of disseminating and raising awareness of practice guidelines. Regarding treatment, since there are no FDA-approved therapies specifically for NASH, the management mainly involves lifestyle improvements and treating comorbidities. However, the study found that physicians commonly prescribed medications such as vitamin E, statins, and metformin for NASH treatment, despite limited evidence for their efficacy. The primary reason for prescribing these medications was weight loss, even though the proven effect on weight reduction varied. The study emphasized the need for consensus on standardizing non-invasive tests for NASH diagnosis and updating practice guidelines to improve the management of this growing epidemic. It's worth noting that the data in this study was collected in 2016 and 2017, and the findings may not reflect current diagnosis and treatment patterns. Additionally, the study focused on a subset of physicians highly engaged in NASH management, which may not represent the broader US population.

Clinical characteristics and management of patients with nonalcoholic steatohepatitis in a real-world setting: analysis of the Ipsos NASH therapy monitor database. BMC gastroenterology **2023; 23:160Shelley K, Articolo A, Luthra R, Charlton M. http://www.ncbi.nlm.nih.gov/pubmed/?term=37208593**

The risk of Rhabdomyolysis; comparing statins

The risk of rhabdomyolysis, is associated with seven types of statins using WHO's pharmacovigilance database, VigiBase®. Among the examined statins, simvastatin was identified as having the highest risk, especially in males above 74 years and in instances of drug interactions. This research is unique as it compares rhabdomyolysis risks across different statins using real-world data. Prior studies, such as clinical trials and network meta-analyses, did not find significant differences between individual statins regarding this adverse drug reaction. The researchers found that the risk factors for rhabdomyolysis included age, gender, drug interactions, and potentially certain health conditions. However, the study has limitations due to the lack of information on drug exposure duration or drug doses and the potential for reporting bias. The research suggests that pravastatin, due to its low risk, should be considered for patients at risk of rhabdomyolysis, thereby informing clinical practices and patient management.

Rhabdomyolysis and statins: a pharmacovigilance comparative study between statins. Br J Clin Pharmacol **2023; Montastruc JL. http://www.ncbi.nlm.nih.gov/pubmed/?term=37186323**

Meta-analysis on MACE reduction in CAS patients using statins

The article "Effect of Statins on Major Adverse Cardiovascular Events in Patients with Coronary Artery Spasm: A Meta-Analysis of the Asia Region" focuses on the impact of statins on patients with coronary artery spasm (CAS) in Asia. CAS, a disease involving localized spasms in coronary arteries, can lead to a variety of serious health complications. Despite statins' proven efficacy in reducing atherosclerotic vascular events, their impact on CAS is not entirely clear. The authors collected data from ten studies, covering 9333 patients, and found that statin use was associated with a significant reduction in major adverse cardiovascular events (MACE) in CAS patients. However, a trial sequential analysis indicated that the available samples were insufficient, necessitating further research. The results were especially significant among Japanese patients and patients followed for over four years. The paper concludes by acknowledging limitations in the meta-analysis, including the lack of randomized control trials and the small sample size, and calls for more

research to confirm the findings. The study overall suggests a potential therapeutic role for statins in CAS patients in Asia.

Effect of Statins on Major Adverse Cardiovascular Events in Patients with Coronary Artery Spasm: A Meta-Analysis of the Asia Region. Cardiovasc Ther 2023; 2023:8807278Zhao TJ, Luo D, Jiang X *et al.* http://www.ncbi.nlm.nih.gov/pubmed/?term=37151221

Early use of high intensity statins showed improved neurological outcomes after SSSI

Are there potential benefits of high-intensity statin therapy in preventing early neurologic deterioration (END) in patients with single small subcortical infarction (SSSI), also known as lacunar infarction. This study aimed to investigate the impact of statin therapy on END prevention and the outcomes of SSSI. The results of the study indicated that early administration of high-intensity statins within 72 hours of symptom onset was associated with a lower incidence of END in patients with SSSI. The study suggests that statins may have a preventive effect on atherosclerosis, inflammation, and plaque stabilization, which are hypothesized mechanisms in the development of END in SSSI. The findings highlight the importance of early treatment with high-intensity statins in improving outcomes for patients with SSSI. Lower rates of END were significantly associated with favorable outcomes in this study.

However, the study has several limitations, including its retrospective nature, single-center design, and inclusion of patients with different SSSI mechanisms. Further randomized clinical trials are needed to validate the findings. Overall, the study suggests that early administration of high-intensity statins within 72 hours could be a potential treatment strategy to improve outcomes in patients with SSSI.

Impact of High-Intensity Statin on Early Neurologic Deterioration in Patients with Single Small Subcortical Infarction. Journal of clinical medicine 2023; 12Jang SH, Park H, Hong JH *et al.* http://www.ncbi.nlm.nih.gov/pubmed/?term=37176701

Algorithm to predict risk for statin related myopathy

This scientific article presents the development and validation of an algorithm to accurately identify statin-induced myopathy (SIM) from electronic health records (EHRs) and investigates the determinants of SIM. The study utilized a diverse cohort of patients receiving various statin regimens from an integrated healthcare delivery system. The algorithm was designed to differentiate true SIM cases from other causes of elevated creatine kinase (CK) levels, which is an objective measure of muscle injury. The algorithm demonstrated good performance metrics, with a sensitivity of 76% and specificity of 77% for detecting the most certain SIM cases. The study identified several clinical conditions associated with elevated CK levels unrelated to statin use, which were used as exclusionary factors in the algorithm. The algorithm-derived SIM cases were then analyzed to determine clinical factors that increase the risk of SIM. The findings revealed a dose-response relationship between statin dose and the odds of statin-induced CK elevation. Higher doses were associated with a higher risk of SIM. Statin type also influenced susceptibility to SIM, with pravastatin showing the strongest association with statin-induced CK elevation. Hypothyroidism was identified as the strongest predictor of SIM, highlighting the importance of monitoring thyroid levels before and during statin therapy. Overall, the developed algorithm provides an efficient and reliable method for identifying SIM cases in EHRs, enhancing the quality of future research on statin-induced myopathy and aiding clinicians in avoiding this adverse effect. The study's findings contribute to a better understanding of SIM determinants and can inform healthcare providers in optimizing statin therapy regimens to minimize adverse outcomes.

Development and application of an algorithm for statin-induced myopathy based on electronic health record-derived structured elements. medRxiv 2023; Oni-Orisan A, Lu M, Peng JA *et al.* http://www.ncbi.nlm.nih.gov/pubmed/?term=37162948

Relevant Publications

Relevant Publications

1. Contemporary Use of Cardiovascular Risk Reduction Strategies in Type 2 Diabetes. Insights from The Diabetes Collaborative Registry. Am Heart J 2023; Arnold SV, Gosch K, Kosiborod M *et al.* http://www.ncbi.nlm.nih.gov/pubmed/?term=37164146
2. A Critical Review of Icosapent Ethyl in Cardiovascular Risk Reduction. Am J Cardiovasc Drugs 2023:1-14Huston J, Schaffner H, Cox A *et al.* http://www.ncbi.nlm.nih.gov/pubmed/?term=37188993
3. Risk of New-Onset Dementia in Patients with Chronic Kidney Disease on Statin Users: A Population-Based Cohort Study. Biomedicines 2023; 11Jong GP, Lin TK, Huang JY *et al.* http://www.ncbi.nlm.nih.gov/pubmed/?term=37189690
4. A Systematic Review and Meta-Analysis of the Incidence and Risk Factors for Major Adverse Cardiovascular Events in Patients with Unrepaired Abdominal Aortic Aneurysms. Biomedicines 2023; 11Sharma C, Singh TP, Thanigaimani S *et al.* http://www.ncbi.nlm.nih.gov/pubmed/?term=37189797
5. Risk of diabetes with statins. Bmj 2023; 381:e071727Mansi IA, Sumithran P, Kinaan M. http://www.ncbi.nlm.nih.gov/pubmed/?term=37172967
6. Atorvastatin and the influence on postoperative atrial fibrillation after surgical aortic valve replacement (STARC) in adults at Odense University Hospital, Denmark: study protocol for a randomised controlled trial. BMJ Open 2023; 13:e069595Krasniqi L, Brandes A, Mortensen PE *et al.* http://www.ncbi.nlm.nih.gov/pubmed/?term=37164465
7. Risk of muscle symptoms while taking statins. Canadian family physician Medecin de famille canadien 2023; 69:337Falk J, Paige A, Dugré N, Allan GM. http://www.ncbi.nlm.nih.gov/pubmed/?term=37172999
8. Sex Differences in the Density of Lipidic Plaque Materials: Insights From the REASSURE-NIRS MultiCenter Registry. Circulation. Cardiovascular imaging 2023:e015107Kataoka Y, Nicholls SJ, Puri R *et al.* http://www.ncbi.nlm.nih.gov/pubmed/?term=37161775
9. Lipid-Lowering Therapy Utilization and Dosage Among Patients with Acute Coronary Syndrome Events: A Retrospective Cohort from 12 Community Hospitals. Clinical epidemiology 2023; 15:547-557Khatib R, Yeh EJ, Glowacki N *et al.* http://www.ncbi.nlm.nih.gov/pubmed/?term=37168051
10. Correlates of Myopathy in Diabetic Patients Taking Statins. Cureus 2023; 15:e37708Tariq S, Goriparthi L, Ismail D *et al.* http://www.ncbi.nlm.nih.gov/pubmed/?term=37206522
11. Serum Cholesterol Differences Between Statin Users Who Take Dietary Supplements and Those Who Do Not: NHANES 2013-2018. Curr Dev Nutr 2023; 7:100007MacDonald TS, Davis KE, Tucker WJ, Miketinas DC. http://www.ncbi.nlm.nih.gov/pubmed/?term=37181126
12. PCSK9 Inhibition in Patients After Heart Transplantation: a Retrospective Review and Literature Analysis. Curr Heart Fail Rep 2023; Chapa JJ, McCollum JC, Bisono JQ *et al.* http://www.ncbi.nlm.nih.gov/pubmed/?term=37155122
13. The Link between Magnesium Supplements and Statin Medication in Dyslipidemic Patients. Curr Issues Mol Biol 2023; 45:3146-3167Nartea R, Mitoiu BI, Ghiorghiu I. http://www.ncbi.nlm.nih.gov/pubmed/?term=37185729
14. New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2022. European heart journal. Cardiovascular pharmacotherapy 2023; Tamargo J, Agewall S, Borghi C *et al.* http://www.ncbi.nlm.nih.gov/pubmed/?term=37169875
15. Therapeutic challenges and cardiovascular risk in patients with HMGCR-associated immune-mediated necrotizing myopathy (HMGR-IMNM) secondary to statins. Eur J Intern Med 2023; Álvarez-Troncoso J, Molina SC, Robles-Marhuenda Á *et al.* http://www.ncbi.nlm.nih.gov/pubmed/?term=37179139
16. Combining serum metabolomic profiles with traditional risk factors improves 10-year cardiovascular risk prediction in people with type 2 diabetes. Eur J Prev Cardiol 2023; Huang Z, Klaric L, Krasauskaite J *et al.* http://www.ncbi.nlm.nih.gov/pubmed/?term=37172216

17. PCSK9 inhibitors for acute coronary syndrome: the era of early implementation. Frontiers in cardiovascular medicine 2023; 10:1138787Chen H, Chen X. http://www.ncbi.nlm.nih.gov/pubmed/?term=37200976
18. Predicting Statin Adherence Following Hospital Discharge for Acute Coronary Syndromes: What's the Score? Heart, lung & circulation 2023; 32:553-554Barlow TR, Karve S, Brieger D, Lowe HC. http://www.ncbi.nlm.nih.gov/pubmed/?term=37169451
19. Emerging Therapies for the Treatment of Atherosclerotic Cardiovascular Disease: From Bench to Bedside. Int J Mol Sci 2023; 24Kumric M, Urlic H, Bozic J *et al.* http://www.ncbi.nlm.nih.gov/pubmed/?term=37175766
20. The effect of discharge care plans on statin prescription rates. Journal of the American Association of Nurse Practitioners 2023; Alleyne D. http://www.ncbi.nlm.nih.gov/pubmed/?term=37167595
21. Real-World Attainment of Low-Density Lipoprotein Cholesterol Goals in Patients at High Risk of Cardiovascular Disease Treated with High-Intensity Statins: The TERESA Study. Journal of clinical medicine 2023; 12Barrios V, Pintó X, Escobar C *et al.* http://www.ncbi.nlm.nih.gov/pubmed/?term=37176627
22. [Current approaches to the treatment of patients with dyslipidemia in the real practice in the outpatient stage]. Kardiologiia 2023; 63:11-15Larina VN, Mironova TN, Larin VG *et al.* http://www.ncbi.nlm.nih.gov/pubmed/?term=37165989
23. Referral rate, profile and degree of control of patients with familial hypercholesterolemia: data from a single lipid unit from a Mediterranean area. Lipids Health Dis 2023; 22:62Serra-Planas E. http://www.ncbi.nlm.nih.gov/pubmed/?term=37170237
24. Fatal hepatic failure following atorvastatin treatment: A case report. Medicine (Baltimore) 2023; 102:e33743Wang H, Liu S, Zhou C, Fu Y. http://www.ncbi.nlm.nih.gov/pubmed/?term=37171309
25. Guidelines for the Neurocritical Care Management of Aneurysmal Subarachnoid Hemorrhage. Neurocritical care 2023; Treggiari MM, Rabinstein AA, Busl KM *et al.* http://www.ncbi.nlm.nih.gov/pubmed/?term=37202712
26. Trends in lipid profiles and control of LDL-C among adults with diabetes in the United States: An analysis of NHANES 2007-2018. Nutrition, metabolism, and cardiovascular diseases : NMCD 2023; Chen T, Wang Z, Xie J *et al.* http://www.ncbi.nlm.nih.gov/pubmed/?term=37156669
27. Medication Adherence and Its Associated Factors Among Outpatients with Heart Failure. Patient preference and adherence 2023; 17:1209-1220Jarab AS, Al-Qerem WA, Hamam HW *et al.* http://www.ncbi.nlm.nih.gov/pubmed/?term=37187575
28. Plasma concentration of atorvastatin metabolites correlates with low-density lipoprotein cholesterol reduction in patients with coronary heart disease. Pharmacol Res Perspect 2023; 11:e01089Sverre E, Munkhaugen J, Kristiansen O *et al.* http://www.ncbi.nlm.nih.gov/pubmed/?term=37186070
29. Impact of atorvastatin reload on the prevention of contrast-induced nephropathy in patients on chronic statin therapy: A prospective randomized trial. PLoS One 2023; 18:e0270000Hammami R, Masmoudi O, Jdidi J *et al.* http://www.ncbi.nlm.nih.gov/pubmed/?term=37155629
30. What is the impact of ongoing statin use on cognitive decline and dementia progression in older adults with mild-moderate Alzheimer disease? PLoS One 2023; 18:e0285529Murphy C, Dyer AH, Lawlor B, Kennelly SP. http://www.ncbi.nlm.nih.gov/pubmed/?term=37167234
31. Evaluation of rosuvastatin-induced QT prolongation risk using real-world data, in vitro cardiomyocyte studies, and mortality assessment. Scientific reports 2023; 13:8108Koo Y, Hyun SA, Choi BJ *et al.* http://www.ncbi.nlm.nih.gov/pubmed/?term=37208484
32. Comparing the effects of four common drug classes on the progression of mild cognitive impairment to dementia using electronic health records. Scientific reports 2023; 13:8102Xu J, Wang F, Zang C *et al.* http://www.ncbi.nlm.nih.gov/pubmed/?term=37208478
33. [Vasoprotective effect of effective lipid-lowering therapy in patients with ST-segment elevation myocardial infarction]. Ter Arkh 2023; 94:1355-1360Salyamova LI,

Khromova AA, Kvasova OG *et al.* http://www.ncbi.nlm.nih.gov/pubmed/?term=37167178
34. [[Translated article]RF- Topical Cholesterol and Statin Formulation to Treat Porokeratosis. Actas Dermosifiliogr 2023; Gimeno Castillo J, De la Torre Gomar FJ. http://www.ncbi.nlm.nih.gov/pubmed/?term=37172901
35. Estimated number and percentage of US adults with atherosclerotic cardiovascular disease recommended add-on lipid-lowering therapy by the 2018 AHA/ACC multi-society cholesterol guideline. Am Heart J Plus 2022; 21Alanaeme CJ, Bittner V, Brown TM *et al.* http://www.ncbi.nlm.nih.gov/pubmed/?term=37168932
36. Veterans Health Administration: Implementation of pharmacogenomic clinical decision support with statin medications and the SLCO1B1 gene as an exemplar. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 2023; Tomcsanyi KM, Tran KA, Bates J *et al.* http://www.ncbi.nlm.nih.gov/pubmed/?term=37210707
37. Bi-allelic variants in HMGCR cause an autosomal-recessive progressive limb-girdle muscular dystrophy. Am J Hum Genet 2023; Morales-Rosado JA, Schwab TL, Macklin-Mantia SK *et al.* http://www.ncbi.nlm.nih.gov/pubmed/?term=37167966
38. Association of Cardiovascular Medications With Adverse Outcomes in a Matched Analysis of a National Cohort of Patients With COVID-19. Am J Med Open 2023; 9:100040Wang LK, Kuo YF, Westra J *et al.* http://www.ncbi.nlm.nih.gov/pubmed/?term=37207280
39. Impact of the COVID-19 pandemic on the management of risk factors in patients with stable atherosclerotic vascular disease. Am J Prev Cardiol 2023; 14:100499Karalis DG, Moeller P, Crawford A *et al.* http://www.ncbi.nlm.nih.gov/pubmed/?term=37193063
40. Variation in Price of Cardiovascular and Diabetes Medicine in Indonesia, and Relationship with Quality: A Mixed Methods Study in East Java. The American journal of tropical medicine and hygiene 2023; Pisani E, Dewi A, Palagyi A *et al.* http://www.ncbi.nlm.nih.gov/pubmed/?term=37160275
41. Availability of healthy foods, fruit and vegetable consumption, and cognition among urban older adults. BMC geriatrics 2023; 23:302Hyun J, Katz MJ, Derby CA *et al.* http://www.ncbi.nlm.nih.gov/pubmed/?term=37198552
42. Digital undergraduate medical education and patient and carer involvement: a rapid systematic review of current practice. BMC Med Educ 2023; 23:335Lawes-Wickwar S, Lovat E, Alao A *et al.* http://www.ncbi.nlm.nih.gov/pubmed/?term=37193974
43. Atorvastatin mucoadhesive tablets in the management of recurrent aphthous stomatitis: a randomized clinical study. BMC oral health 2023; 23:285Molania T, Akbari J, Babaei A *et al.* http://www.ncbi.nlm.nih.gov/pubmed/?term=37179286
44. Optimizing lipid management-impact of the COVID 19 pandemic upon cardiovascular risk in England. Br Med Bull 2023; Newton JL, Hamed J, Williams H *et al.* http://www.ncbi.nlm.nih.gov/pubmed/?term=37170945
45. Effect of in-hospital evolocumab therapy on lipoprotein(a) in patients with acute myocardial infarction: a retrospective cohort study and a propensity score matching analysis. Cardiol Plus 2023; 8:46-52Gao G, Zheng T, Lan B *et al.* http://www.ncbi.nlm.nih.gov/pubmed/?term=37187811
46. Genetic Testing Enables the Diagnosis of Familial Hypercholesterolemia Underdiagnosed by Clinical Criteria: Analysis of Japanese Early-Onset Coronary Artery Disease Patients. Cardiology research and practice 2023; 2023:2236422Miyama H, Katsumata Y, Momoi M *et al.* http://www.ncbi.nlm.nih.gov/pubmed/?term=37151871
47. A population pharmacokinetic and pharmacokinetic-pharmacodynamic analysis of vupanorsen from phase I and phase II studies. CPT Pharmacometrics Syst Pharmacol 2023; Ahn JE, Terra SG, Liu J. http://www.ncbi.nlm.nih.gov/pubmed/?term=37170423
48. From Angiopoietin-2 to basic chemistry: differential effects of statins on endothelial homeostasis in ARDS. Crit Care 2023; 27:183Hofmaenner DA, David S. http://www.ncbi.nlm.nih.gov/pubmed/?term=37173753
49. The Involvement of Hypoxia in the Response of Neuroblastoma Cells to the Exposure of Atorvastatin. Curr Issues Mol Biol 2023; 45:3333-3346Correia AS, Marques L, Vale

N. http://www.ncbi.nlm.nih.gov/pubmed/?term=37185742
50. Therapeutic Effects of Statins: Promising drug for Topical and Transdermal Administration. Curr Med Chem 2023; Zahedipour F, Hosseini SA, Reiner Ž *et al.* http://www.ncbi.nlm.nih.gov/pubmed/?term=37157198
51. Prior Statin vs In-Hospital Statin Usage in Severe COVID-19: Review and Meta-Analysis. Curr Probl Cardiol 2023:101810Alhallak I, Paydak H, Mehta JL. http://www.ncbi.nlm.nih.gov/pubmed/?term=37211301
52. Potentially Harmful Drug-Drug Interactions and Their Associated Factors Among Hospitalized Cardiac Patients: A Cross-Sectional Study. Drugs - real world outcomes 2023; Kalash A, Abdelrahman A, Al-Zakwani I, Al Suleimani Y. http://www.ncbi.nlm.nih.gov/pubmed/?term=37178272
53. The prevalent new-user design for studies with no active comparator: The example of statins and cancer. Epidemiology 2023; Suissa S, Dell'Aniello S, Renoux C. http://www.ncbi.nlm.nih.gov/pubmed/?term=37195285
54. Effects of long-term regular oral aspirin combined with atorvastatin to prevent ischemic stroke on human gut microbiota. Eur J Pharmacol 2023; 951:175800Chen G, Wang Z, Song W *et al.* http://www.ncbi.nlm.nih.gov/pubmed/?term=37201625
55. Simvastatin ameliorates testosterone-induced prostatic hyperplasia in rats via modulating IGF-1/PI3K/AKT/FOXO signaling. Eur J Pharmacol 2023; 950:175762El-Shafei NH, Zaafan MA, Kandil EA, Sayed RH. http://www.ncbi.nlm.nih.gov/pubmed/?term=37164119
56. Association Between the Use of Statins and Risk of Interstitial Lung Disease/Idiopathic Pulmonary Fibrosis: Time-Dependent Analysis of Population-Based Nationwide Data. The European respiratory journal 2023; Jang HJ, Lee DY, Loloci G *et al.* http://www.ncbi.nlm.nih.gov/pubmed/?term=37202155
57. A bibliometric analysis and visualization of literature on non-fasting lipid research from 2012 to 2022. Frontiers in endocrinology 2023; 14:1136048Hou Y, An Z, Hou X *et al.* http://www.ncbi.nlm.nih.gov/pubmed/?term=37152935
58. Assessing the role of lipid-lowering therapy on multi-cancer prevention: A mendelian randomization study. Frontiers in pharmacology 2023; 14:1109580Min Y, Wei X, Liu Z *et al.* http://www.ncbi.nlm.nih.gov/pubmed/?term=37153802
59. A systematic review on sex differences in adverse drug reactions related to psychotropic, cardiovascular, and analgesic medications. Frontiers in pharmacology 2023; 14:1096366Shan Y, Cheung L, Zhou Y *et al.* http://www.ncbi.nlm.nih.gov/pubmed/?term=37201021
60. A Systematic Review and Meta-Analysis on the Impact of Statin Treatment in HIV Patients on Antiretroviral Therapy. International journal of environmental research and public health 2023; 20Mokgalaboni K, Phoswa WN, Yates S *et al.* http://www.ncbi.nlm.nih.gov/pubmed/?term=37174188
61. Confirmation of Statin and Fibrate Use from Small-Volume Archived Plasma Samples by High-Throughput LC-MS/MS Method. Int J Mol Sci 2023; 24Kusovschi JD, Ivanova AA, Gardner MS *et al.* http://www.ncbi.nlm.nih.gov/pubmed/?term=37175638
62. Rosuvastatin Synergistically Enhances the Antinociceptive Efficacy of Duloxetine in Paclitaxel-Induced Neuropathic Pain in Mice. Int J Mol Sci 2023; 24Lobos N, Lux S, Zepeda RJ *et al.* http://www.ncbi.nlm.nih.gov/pubmed/?term=37176065
63. Effect of pharmacologic anti-atherosclerotic therapy on carotid intraplaque neovascularization: A systematic review. J Clin Lipidol 2023; Cui E, Kersche G, Grubic N *et al.* http://www.ncbi.nlm.nih.gov/pubmed/?term=37173161
64. The clinical effects of inclisiran, a first-in-class LDL-C lowering siRNA therapy, on the LDL-C levels in Chinese patients with hypercholesterolemia. J Clin Lipidol 2023; Luo Z, Huang Z, Sun F *et al.* http://www.ncbi.nlm.nih.gov/pubmed/?term=37164838
65. Information regarding polypill treatment is lacking. Kidney international 2023; 103:1201Dufour I, Devresse A. http://www.ncbi.nlm.nih.gov/pubmed/?term=37210198
66. Adjunctive therapy with lipid-lowering agents in COVID-19: a systematic review and meta-analysis of randomized controlled trials. Lipids Health Dis 2023; 22:61Khalaji A, Behnoush AH, Alilou S *et al.* http://www.ncbi.nlm.nih.gov/pubmed/?term=37158917
67. [Not Available]. MMW Fortschritte der Medizin 2023; 165:16Schlimpert V. http://www.ncbi.nlm.nih.gov/pubmed/?term=37155041

68. A phase 1 study of simvastatin in combination with topotecan and cyclophosphamide in pediatric patients with relapsed and/or refractory solid and CNS tumors. Pediatric blood & cancer 2023:e30405Cash T, Jonus HC, Tsvetkova M *et al.* http://www.ncbi.nlm.nih.gov/pubmed/?term=37158620
69. Safety Profile of the Concomitant Use of Atorvastatin and Cyclosporine in Renal Transplant Recipients. Pharmazie 2023; 78:47-50Harabayashi R, Takahashi M, Takahashi K *et al.* http://www.ncbi.nlm.nih.gov/pubmed/?term=37189269
70. Post-diagnostic metformin and statin use and risk of biochemical recurrence in Veterans diagnosed with prostate cancer. Prostate 2023; Khan S, Chang SH, Seyerle AA *et al.* http://www.ncbi.nlm.nih.gov/pubmed/?term=37191401
71. [Severe rhabdomyolysis associated with atorvastatin. Case report]. Rev Med Inst Mex Seguro Soc 2023; 61:245-250Medina-Romero J, Toledo-Salinas O, Reyes-Álvarez FJ, Gómez-Flores SS. http://www.ncbi.nlm.nih.gov/pubmed/?term=37207311
72. [Efficacy and safety of the use of alirocumab in real clinical practice]. Ter Arkh 2023; 94:1401-1406Korneva VA, Kuznetsova TY, Scopets IS, Vezikova NN. http://www.ncbi.nlm.nih.gov/pubmed/?term=37167185
73. Could statin improve outcomes after pipeline embolization for intracranial aneurysms in a real-world setting? Therapeutic advances in neurological disorders 2023; 16:17562864231170517Wang X, Turhon M, Yang X *et al.* http://www.ncbi.nlm.nih.gov/pubmed/?term=37187463
74. Association of chronic statin use, myopenia, myosteatosis and major morbidity in surgical patients with upper gastrointestinal cancer. Updates in surgery 2023; Cereda M, Bernasconi DP, Uggeri F *et al.* http://www.ncbi.nlm.nih.gov/pubmed/?term=37202600
75. Dexamethasone and Statins in Patients Undergoing Primary Middle Meningeal Artery Embolization for Chronic Subdural Hematoma: A Propensity-Matched Study in the TriNetX Research Network. World neurosurgery 2023; Sioutas GS, Mannam SS, Tarbay AC *et al.* http://www.ncbi.nlm.nih.gov/pubmed/?term=37164211

Basic Science

1. Correction to: Association of statin pretreatment with presentation characteristics, infarct size and outcome in older patients with acute coronary syndrome: the Elderly ACS-2 trial. Age and ageing 2023; 52. http://www.ncbi.nlm.nih.gov/pubmed/?term=37211368
2. Modulators of cellular cholesterol homeostasis as antiproliferative and model membranes perturbing agents. Biochimica et biophysica acta. Biomembranes 2023; 1865:184163Błaszczyk M, Kozioł A, Palko-Łabuz A *et al.* http://www.ncbi.nlm.nih.gov/pubmed/?term=37172710
3. Atorvastatin liposomes in a 3D-printed polymer film: a repurposing approach for local treatment of oral candidiasis. Drug delivery and translational research 2023; Nour EM, El-Habashy SE, Shehat MG *et al.* http://www.ncbi.nlm.nih.gov/pubmed/?term=37184748
4. A Targeted, Low-Throughput Compound Screen in a Drosophila Model of Neurofibromatosis Type 1 Identifies Simvastatin and BMS-204352 as Potential Therapies for Autism Spectrum Disorder (ASD). eNeuro 2023; 10Dyson A, Ryan M, Garg S *et al.* http://www.ncbi.nlm.nih.gov/pubmed/?term=37185294
5. Atorvastatin Attenuates Diet-Induced Non-Alcoholic Steatohepatitis in APOE*3-Leiden Mice by Reducing Hepatic Inflammation. Int J Mol Sci 2023; 24Inia JA, Stokman G, Pieterman EJ *et al.* http://www.ncbi.nlm.nih.gov/pubmed/?term=37175538
6. Effect of simvastatin treatment on mitochondrial function and inflammatory status of human white adipose tissue. J Clin Endocrinol Metab 2023; Bager Christensen I, Blom I, Dohlmann TL *et al.* http://www.ncbi.nlm.nih.gov/pubmed/?term=37161534

7. **The Effect of Simvastatin on the Dynamics of NF-κB-Regulated Neurodegenerative and Neuroprotective Processes in the Acute Phase of Ischemic Stroke. Mol Neurobiol 2023; Lietzau G, Sienkiewicz W, Karwacki Z *et al.* http://www.ncbi.nlm.nih.gov/pubmed/?term=37204689**
8. **Proof-of-concept study for liver-directed miQURE technology in a dyslipidemic mouse model. Mol Ther Nucleic Acids 2023; 32:454-467Zancanella V, Vallès A, Liefhebber JMP *et al.* http://www.ncbi.nlm.nih.gov/pubmed/?term=37168797**
9. **Efficacy of spongy xenogeneic scaffold loaded with simvastatin in the treatment of severe alveolar horizontal defect: A clinical and histological study. Nigerian journal of clinical practice 2023; 26:369-375Esmaeili V, Boostani H, Ahmadpour F. http://www.ncbi.nlm.nih.gov/pubmed/?term=37203098**

To subscribe to the Statin Literature Update Service Click HERE

Facebook Twitter Website

mailing address:
lansberg@gmail.com